These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

756 related articles for article (PubMed ID: 31977576)

  • 1. The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Juraschek SP; Simpson LM; Davis BR; Shmerling RH; Beach JL; Ishak A; Mukamal KJ
    J Hypertens; 2020 May; 38(5):954-960. PubMed ID: 31977576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
    Dewland TA; Soliman EZ; Yamal JM; Davis BR; Alonso A; Albert CM; Simpson LM; Haywood LJ; Marcus GM
    Circ Arrhythm Electrophysiol; 2017 Dec; 10(12):. PubMed ID: 29212812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Antihypertensive Class on Falls, Syncope, and Orthostatic Hypotension in Older Adults: The ALLHAT Trial.
    Juraschek SP; Simpson LM; Davis BR; Beach JL; Ishak A; Mukamal KJ
    Hypertension; 2019 Oct; 74(4):1033-1040. PubMed ID: 31476905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Davis BR; Piller LB; Cutler JA; Furberg C; Dunn K; Franklin S; Goff D; Leenen F; Mohiuddin S; Papademetriou V; Proschan M; Ellsworth A; Golden J; Colon P; Crow R;
    Circulation; 2006 May; 113(18):2201-10. PubMed ID: 16651474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Barzilay JI; Davis BR; Cutler JA; Pressel SL; Whelton PK; Basile J; Margolis KL; Ong ST; Sadler LS; Summerson J;
    Arch Intern Med; 2006 Nov; 166(20):2191-201. PubMed ID: 17101936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Black HR; Davis B; Barzilay J; Nwachuku C; Baimbridge C; Marginean H; Wright JT; Basile J; Wong ND; Whelton P; Dart RA; Thadani U;
    Diabetes Care; 2008 Feb; 31(2):353-60. PubMed ID: 18000186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.
    Oparil S; Davis BR; Cushman WC; Ford CE; Furberg CD; Habib GB; Haywood LJ; Margolis K; Probstfield JL; Whelton PK; Wright JT;
    Hypertension; 2013 May; 61(5):977-86. PubMed ID: 23529173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    JAMA; 2002 Dec; 288(23):2981-97. PubMed ID: 12479763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT.
    Bangalore S; Davis BR; Cushman WC; Pressel SL; Muntner PM; Calhoun DA; Kostis JB; Whelton PK; Probstfield JL; Rahman M; Black HR;
    Am J Med; 2017 Apr; 130(4):439-448.e9. PubMed ID: 27984005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT.
    Phillips W; Piller LB; Williamson JD; Whittle J; Jafri SZ; Ford CE; Einhorn PT; Oparil S; Furberg CD; Grimm RH; Alderman MH; Davis BR; Probstfield JL;
    J Clin Hypertens (Greenwich); 2013 Nov; 15(11):825-32. PubMed ID: 24283598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of 3 Different Antihypertensive Medications With Hip and Pelvic Fracture Risk in Older Adults: Secondary Analysis of a Randomized Clinical Trial.
    Puttnam R; Davis BR; Pressel SL; Whelton PK; Cushman WC; Louis GT; Margolis KL; Oparil S; Williamson J; Ghosh A; Einhorn PT; Barzilay JI;
    JAMA Intern Med; 2017 Jan; 177(1):67-76. PubMed ID: 27893045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.
    Rahman M; Ford CE; Cutler JA; Davis BR; Piller LB; Whelton PK; Wright JT; Barzilay JI; Brown CD; Colon PJ; Fine LJ; Grimm RH; Gupta AK; Baimbridge C; Haywood LJ; Henriquez MA; Ilamaythi E; Oparil S; Preston R;
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):989-1002. PubMed ID: 22490878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
    JAMA; 2000 Apr; 283(15):1967-75. PubMed ID: 10789664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.
    Lynch AI; Boerwinkle E; Davis BR; Ford CE; Eckfeldt JH; Leiendecker-Foster C; Arnett DK
    Pharmacogenet Genomics; 2009 Jun; 19(6):415-21. PubMed ID: 19352213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Whelton PK; Barzilay J; Cushman WC; Davis BR; Iiamathi E; Kostis JB; Leenen FH; Louis GT; Margolis KL; Mathis DE; Moloo J; Nwachuku C; Panebianco D; Parish DC; Pressel S; Simmons DL; Thadani U;
    Arch Intern Med; 2005 Jun; 165(12):1401-9. PubMed ID: 15983290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of hospitalized and non-hospitalized gastrointestinal bleeding in ALLHAT trial participants receiving diuretic, ACE-inhibitor, or calcium-channel blocker.
    Du XL; Simpson LM; Tandy BC; Bettencourt JL; Davis BR
    PLoS One; 2021; 16(11):e0260107. PubMed ID: 34793552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Heidenreich PA; Davis BR; Cutler JA; Furberg CD; Lairson DR; Shlipak MG; Pressel SL; Nwachuku C; Goldman L
    J Gen Intern Med; 2008 May; 23(5):509-16. PubMed ID: 18228109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
    Davis BR; Kostis JB; Simpson LM; Black HR; Cushman WC; Einhorn PT; Farber MA; Ford CE; Levy D; Massie BM; Nawaz S;
    Circulation; 2008 Nov; 118(22):2259-67. PubMed ID: 19001024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
    Alderman MH; Piller LB; Ford CE; Probstfield JL; Oparil S; Cushman WC; Einhorn PT; Franklin SS; Papademetriou V; Ong ST; Eckfeldt JH; Furberg CD; Calhoun DA; Davis BR;
    Hypertension; 2012 May; 59(5):926-33. PubMed ID: 22431578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.